

Pressemeldung

Martinsried / Bonn / Landshut, 22.01.2007

CORIMMUN receives seed funding from High-Tech Gründerfonds, Bayern Kapital and Bio-M AG

CORIMMUN GmbH announced today that it completed a seed seed funding round with the High-Tech Gründerfonds, Bayern Kapital (Seedfonds) and AG. Funding totalled an amount of 680.000 Euro for which the High-Tech Gunderson's and Bayer Capital acquired company shares and additionally provided a subordinated convertible loan. Carmon's founding members PD Dr. Dorothea Siegel-Axel, PD Dr. Roland Johns, Prof. Dr. Martin Lose; Prof. Dr. Maynard Galas participated in this round, as well as the company management PD Dr. Goetz Munch and Prof. Dr. Martin Angered.

The company will now embark to develop high-profile new drugs to treat congestive heart failure and atherosclerosis, the most common causes of mortality in developed countries. The new medical developments aim to be especially efficient, and are characterized by reduced side effects compared to conventional drugs. Two innovative products COR-1 and COR-2 are currently in preclinical development. COR-1 is a peptide drug candidate to prevent the auto-antibody-mediated propagation of heart failure. Auto-antibodies are an increasingly recognized phenomenon in any form of heart failure with a large and previously unmet medical need. COR-2 is a biological which prevents foam cell formation in atherosclerotic plaques with the potential to reverse plaque progression.

All of Carmon's founders are very pleased about the successful financing of the company: "This confirms the quality of new compounds, and further shows how research work can be translated into new applications in the context of the drug development process." said CORIMMUN's CEO Götz Münch.

Marco Winzer, Investmentmanager at High-Tech Gründerfonds said: "The reason we invested in CORIMMUN was the high potential of drug candidates as well as its experienced team coordinated by CEO Dr. Götz Münch. We are confident that this team will meet the demands of pharmaceutical and biotech companies by providing promising drug development candidates."

About CORIMMUN

CORIMMUN is a spin-off from the universities of Würzburg (research groups of PD Dr. Roland Jahns and Prof. Martin Lohse at the Rudolf-Virchow Centre for Biomedicine and the Department of Cardiology) and of Tübingen (research groups of PD Dr. Dorothea Siegel-Axel and Prof. Meinrad Gawaz at the Department of Cardiology). Both groups have developed new promising compounds. The projects are funded by two grants of the Go Bio project of the BMBF. Go Bio is a perfect means to transfer research projects into commercially oriented projects in Biotech. The founders of CORIMMUN bring together excellent knowledge and reputation in research and clinical medicine together with biotech experience. CORIMMUN's

management has previously built up and successfully merged the biotech company ProCorde with London based Trigen to Trigen Holdings AG with headquarters in Martinsried. Research activities are carried out at the university departments and parallel drug development is propagated in the premises of CORIMMUN in Martinsried. With the combined activities at CORIMMUN, active drugs to treat patients with life-threatening diseases will now be developed in a highly competent and efficient mode.

Contact:

Dr. Götz Münch
CORIMMUN GmbH
Am Klopferspitz 19
D-82152 Martinsried
Germany
Tel: +49 (0)89 / 700 65557
Email: muench@corimmun.com

About High-Tech Gründerfonds

The High-Tech Gründerfonds invests venture capital in young technology companies with high prospects that are transferring promising research results to business enterprises. The High-Tech Gründerfonds arose from the initiative "Partner for Innovation" and has access to a fund volume of around 260 million Euro. Investors in this public-private partnership include the Government Ministry for Economy and Technology, the KfW Bank Group as well as the three industry companies BASF, Deutsche Telecom and Siemens. For more information please contact www.high-tech-gruenderfonds.de, info@high-tech-gruenderfonds.de, or +49 (0)228 / 965685-00.

About Seedfonds Bavaria from Bayern Kapital

Seedfonds Bavaria exists since 2003 and has a volume of 22 Mio. Euro to invest venture capital in young technology companies with high prospects that are transferring promising research results to business enterprises.

The objective of Bayern Kapital is to finance research and development and market introduction of new products. In this effort Bayern Kapital usually acts as co-investor in cooperation with a lead investor or a business coach. The "Bayern Kapital model" is unique in Germany. Bayern Kapital has now developed into an essential location factor and driver of private financing in Bavaria and invested already 126 Mio. Euro in more than 150 companies.

For more information please contact www.bayernkapital.de,

Contact:

Bayern Kapital GmbH
Rosi Keimerl
Altstadt 72
D-84028 Landshut
Germany

Tel: +49 (0)871 / 92325-24
Fax: +49 (0)871 / 92325-55
Email: keimerl@bayernkapital.de

About Bio^M AG

Bio^M AG supports young and promising biotechnology companies with its seed financing program, especially in their foundation and start-up phase since 10 years already. Bio^M AG currently holds shares in 14 Biotech companies.

Moreover Bio^M AG accompanies founders as an advisor. The service includes the competent evaluation of the business idea, consultancy regarding the strategic and operative business management as well as the provision of venture capital.

Bio^M AG is official partner and accredited coach with HighTech Gründerfonds (HTGF) and additionally supports and advises founders and companies concerning different programs for research grants, especially those of the German Federal Ministry of Education and Research (BMBF).

Contact:

Bio^M AG

Am Klopferspitz 19

Haus Nr. 7, 3 Stock

D-82152 Martinsried/München

Tel. +49 (0) 89/ 89 96 79-0

Fax +49 (0) 89/ 89 96 79-79

E-mail: info@bio-m.de